WEBULL
News
PHVS
25.74
-0.08%
-0.02
Weekly Report: what happened at PHVS last week (1222-1226)?
Weekly Report · 1d ago
Why Pharvaris (PHVS) Is Up 13.3% After RAPIDe-3 Success And 2026 Deucrictibant Filing Plans
Simply Wall St · 12/23 03:22
Morgan Stanley Reaffirms Their Buy Rating on Pharvaris (PHVS)
TipRanks · 12/22 14:06
Weekly Report: what happened at PHVS last week (1215-1219)?
Weekly Report · 12/22 09:03
3 ‘Strong Buy’ Stocks to Buy Now, 12/15/2025, According to Top Analysts
TipRanks · 12/16 03:50
Pharvaris (PHVS) Is Down 5.7% After Pivotal RAPIDe-3 Deucrictibant Data And 2026 Filing Plan
Simply Wall St · 12/16 01:27
Pharvaris (PHVS) Receives a Buy from Morgan Stanley
TipRanks · 12/15 14:05
Weekly Report: what happened at PHVS last week (1208-1212)?
Weekly Report · 12/15 09:03
Pharvaris (NasdaqGS:PHVS): Reassessing Valuation After RAPIDe-3 Phase 3 Success and Deucrictibant Commercial Progress
Simply Wall St · 12/14 13:11
Weekly Report: what happened at PHVS last week (1201-1205)?
Weekly Report · 12/08 09:03
Pharvaris (PHVS): Reassessing Valuation After Strong RAPIDe-3 Phase 3 Success in Hereditary Angioedema
Simply Wall St · 12/06 18:14
Pharvaris Is Maintained at Outperform by Oppenheimer
Dow Jones · 12/04 18:20
Oppenheimer Maintains Outperform on Pharvaris, Raises Price Target to $50
Benzinga · 12/04 18:09
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
NASDAQ · 12/04 18:09
Pharvaris Is Maintained at Buy by Guggenheim
Dow Jones · 12/04 14:04
Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $39
Benzinga · 12/04 13:54
Pharvaris Is Maintained at Overweight by Morgan Stanley
Dow Jones · 12/04 13:14
Pharvaris (PHVS) Receives a Buy from Oppenheimer
TipRanks · 12/04 13:08
Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $41
Benzinga · 12/04 13:04
Pharvaris price target raised to $50 from $44 at Oppenheimer
TipRanks · 12/04 12:35
More
Webull provides a variety of real-time PHVS stock news. You can receive the latest news about Pharvaris N.V. through multiple platforms. This information may help you make smarter investment decisions.
About PHVS
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.